T cell Bim levels reflect responses to anti–PD-1 cancer therapy

Immune checkpoint therapy with PD-1 blockade has emerged as an effective therapy for many advanced cancers; however, only a small fraction of patients achieve durable responses. To date, there is no validated blood-based means of predicting the response to PD-1 blockade. We report that Bim is a down...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: Dronca, Roxana S., Liu, Xin, Harrington, Susan M., Chen, Lingling, Cao, Siyu, Kottschade, Lisa A., McWilliams, Robert R., Block, Matthew S., Nevala, Wendy K., Thompson, Michael A., Mansfield, Aaron S., Park, Sean S., Markovic, Svetomir N., Dong, Haidong
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4863706/
https://ncbi.nlm.nih.gov/pubmed/27182556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.86014
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi